BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Unsold Rams May Be Less expensive Than You Suspect - 2The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- 310 Demonstrated Systems to Develop Your Internet based Business
- 4Vote in favor of the bloom plan that adds a bit of excellence to your life!
- 55 Breakout Stars in Ongoing television Series
- Commonsense Ways to work on Your Funds with a Restricted Pay
- Winter virus season so far is not too bad, but doctors worry about suffering to come
- What to know about voluntary chocolate recall
- Auschwitz Committee wants German auction of Holocaust items scrapped
- King Charles III says he is reducing cancer treatment schedule in 2026
- Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- Saturn shines with the waxing moon at sunset on Nov. 29
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- King Charles shares cancer treatment update, says it's a 'personal blessing'
